Effects of microgram doses of haloperidol on open-field behavior in mice

Pharmacology Biochemistry and Behavior

Volumn 53, Issue 4, 1996, Pages 833-838

  Conceição, Isaltino Marcelo ^a   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amphetamine; Apomorphine; Bromocriptine; Haloperidol; Open field test

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALIA;

EID: 0343961973     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02085-3     Document Type: Article

References (44)

1. Alfredsson, G.; Härnryd, C.; Wiesel, F.-A. Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patitents: Relationship to drug concentrations. Psychopharmacology 84:237-241; 1984.
2. Andén, N. E.; Grabowska-Andén, M. Presynaptic and postsynaptic effects of dopamine receptor blocking agents. Adv. Neurol. 24:235-245; 1979.
3. Andreasen, N. C. Negative syndrome in schizophrenia: Strategies for long-term management. In: Kemali, D.; Racagni, G., eds. Chronic treatment in neuropsychiatry. New York: Raven Press; 1985:1-6.
4. Bernardi, M. M.; De Souza, H.; Palermo-Neto, J. Effects of single and long-term haloperidol administration on open-field behavior of rats. Psychopharmacology 73:175-188; 1981.
5. Bernardi, M. M.; Palermo-Neto, J. Effects of apomorphine administration on locomotor activity of control and experimental rats withdrawn from long-term haloperidol treatment. Gen. Pharmacol. 14:545-547; 1983.
6. Bernardi, M. M.; Palermo-Neto, J. Effects of apomorphine administration on rearing activity of control and experimental rats withdrawn from long-term haloperidol treatment. Gen. Pharmacol. 15:363-365; 1984.
7. Capaz, F. R.; Vasconcelos, L. E. M.; De Moraes, S.; Palermo-Neto, J. The open-field: A simple method to show ethanol withdrawal symptoms. Arch. Int. Pharmacodyn. Ther. 251:228-236; 1981.
8. Carlsson, A. Receptor-mediated control of dopamine metabolism. In: Usdin, E.; Snyder, S., eds. Pre and postsynaptic receptors. New York: Dekker; 1975:49-63.
9. Carroll, J. B.; Curtis, G. C.; Kokman, E. Paradoxical response to dopamine agonists in tardive dyskinesia. Am. J. Psychiatry 134:785-789; 1977.
10. Corsini, G. U.; Del Zompo, M.; Marconi, S.; Cianchetti, C.; Mangoni, A.; Gessa, G. L. Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv. Biochem. Psychopharmacol. 16:645-648; 1977.
11. Costall, B.; Naylor, R. J. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacology 34:233-241; 1974.
12. Costall, B.; Kwanglim, S.; Naylor, R. J. Characterization of the mechanism by which purported DA agonists reduce locomotor activity in mice. Eur. J. Pharmacol. 73:175-188; 1981.
13. Creese, I.; Iversen, S. D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain. Res. 83: 419-436; 1975.
14. Cutler, N. R.; Jeste, D. V.; Kaufman, C. A.; Karoum, F.; Schran, H. F.; Wyatt, R. J. Low dose bromocriptine: A study of acute effects in chronic medicated schizophrenics. Prog. Neuropsychopharmacol. Biol. Psychiatry 8:277-283; 1984.
15. Di Chiara, G.; Porceddu, M. L.; Vargiu, L.; Argiolas, A.; Gessa, G. L. Evidence for dopamine receptor mediating sedation in the mouse brain. Nature 264:564-567; 1976.
16. 2 dopamine autoreceptor drugs: Do they really exist? Life Sci. 47:361-376; 1990.
17. Feinberg, M.; Carrol, B. J. Effects of dopamine agonists and antagonists in Tourette's disease. Arch. Gen. Psychiatry 36:979-985; 1979.
18. Frussa-Filho, R.; Palermo-Neto, J. Effects of single and long-term administration of sulpiride on open-field and stereotyped behavior of rats. Braz. J. Med. Biol. Res. 23:463-472; 1990.
19. Jackson, D. M.; Jenkins, O. F.; Ross, S. B. The motor effects of bromocriptine: A review. Psychopharmacology 95:433-466; 1988.
20. Johnson, A. M.; Loew, D. M.; Vigouret, J.-M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. Br. J. Pharmacol. 56:59-68; 1976.
21. Johnson, N.; Leone, F. Statistics and experimental design. In: Usdin, E.; Snyder, S., eds. Pre-and postsynaptic receptors. New York: John Wiley; 1974.
22. Kebabian, J. M.; Calne, D. B. Multiple receptors for dopamine. Nature 277:93-96; 1979.
23. Kelly, P. H.; Seviour, P. W.; Iversen, S. D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens, septi and corpus striatum. Brain Res. 94: 507-522; 1975.
24. Ljungberg, T.; Ungerstedt, U. Automatic registration of behavior related to dopamine and noradrenaline transmission. Eur. J. Pharmacol. 36:181-188; 1976.
25. 1 agonist SK&F 38393. Neuropharmacology 25:947-949; 1986.
26. Meller, E.; Enz, A.; Goldstein, M. Absence of reserve at striatal dopamine receptors regulating cholinergic neuronal activity. Eur. J. Pharmacol. 155:151-154; 1988.
27. Meller, E.; Helmer-Matyjek, R.; Bohmaker, K.; Adler, C. H.; Friedhoff, A. J.; Goldstein, M. Receptor reserve at striatal dopamine autorreceptors: Implications for selectivity of dopamine agonists. Eur. J. Pharmacol. 123:311-314; 1986.
28. Meltzer, H. Y.; Kolakowska, T.; Robertson, A.; Tricou, B. J. Effects of low dose bromocriptine in treatment of psychosis: The dopamine autoreceptor-stimulation strategy. Psychopharmacology 81:37-41; 1983.
29. Ögren, S.-O.; Rodebjer, A.; Angeby, K. The "presynaptic" blocking potency of sulpiride and haloperidol in the rat is age dependent. Neurosci. Lett. 46:203-207; 1984.
30. 2 receptors regulating rat locomotor activity. Psychopharmacology 99:558-562; 1989.
31. Puech, A.; Simon, P.; Boissier, J. R. Benzamides and classical neuroleptics: Comparison of their actions using six apomorphine-induced effects. Eur. J. Pharmacol. 50:261-300; 1978.
32. Seeman, P.; Van Tol, H. M. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15:264-270; 1994.
33. Sibley, D. R.; Monsma, J. J. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13:61-69; 1992.
34. Smith, R. C.; Taminga, C.; Davis, J. M. Effect of apomorphine on schizophrenic symptoms. J. Neural Transm. 40:171-176; 1977.
35. Ståhle, L. Do autoreceptors mediate dopamine agonist-induced yawing and suppression of exploration? Psychopharmacology 106:1-13; 1992.
36. Ståhle, L.; Ungerstedt, U. Yawning and suppression of exploration in amphetamine-treated rats: Incompatibility with the autoreceptor hypothesis. Psychopharmacology 97:553-560; 1989.
37. 2 agonists and antagonists on velocity of movements, rearing and grooming in the mouse. Neuropharmacology 25:445-453; 1986.
38. Strömbom, U. Antagonism by haloperidol of locomotor depression induced by small doses of apomorphine. J. Neural Transm. 40:191-194; 1977.
39. Strömbom, U. Cathecholamine receptor agonists: Effects on motor activity and tyrosine hydroxilation in mouse brain. Naunyn-Schmied. Arch. Pharmacol. 292:167-176; 1976.
40. Sumners, C.; DeVries, J. B.; Horn, A. S. Behavioral and neurochemical studies on apomorphine-induced hypomotility in mice. Neuropharmacology 20:1203-1208; 1981.
41. Taminga, C. A.; Gerlach, J. New neuroleptics and experimental antispychotics in schizophrenia. In: Meltzer, H. Y., ed. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987:1129-1140.
42. Tolosa, E. S. Modification of tardive dyskinesia and spasmodic torticollis by apomorphine. Arch. Neurol. 35:459-462; 1978.
43. Tolosa, E. S.; Sparber, S. B. Apomorphine in Huntington's chorea: Clinical observations and theoretical consideration. Life Sci. 15:1371-1380; 1974.
44. Ungerstedt, U.; Herrera-Marschitz, M.; Ståhle, L.; Tossman, U.; Zetterström, T. Dopamine receptor mechanism studies by correlating transmitter release and behaviour. Acta Pharm. Suec. Suppl 1:165-181; 1983.